HealthcareNasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 1010086SIGA stock profile & AI dashboard →

13F Pro Quality Score

73.6/100

Rank #190 of 2,879 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

90.7/100

Profitability

90.5/100

Balance Sheet

89.2/100

Earnings Quality

92.7/100

Free Cash Flow

93.2/100

Institutional Flow

26.3/100

Revenue Scale

17.3/100

Dilution Risk

29.4/100

SIGA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SIGA TECHNOLOGIES INC (SIGA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SIGA at 73.6/100 on a 32-signal composite quality model, placing it at rank #190 of 2,879 stocks — the top 10% of the AI-ranked universe. SIGA scores in the top quartile across free cash flow (93.2), earnings quality (92.7), revenue growth (90.7). Areas of concern include revenue scale (17.3) and institutional flow (26.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 29.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SIGA TECHNOLOGIES INC reports quarterly revenue of $6.2M, net income of $-3.5M, free cash flow of $-8.7M. Top institutional holders of SIGA by reported 13-F value include BlackRock,, DIMENSIONAL FUND ADVISORS, AltraVue Capital,, based on the most recent SEC filings. SIGA trades on the Nasdaq exchange and files with the SEC under CIK 1010086. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SIGA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SIGA TECHNOLOGIES INC directly from SEC EDGAR. SIGA TECHNOLOGIES INC's 13F Pro composite quality score has ranged between 36 and 76 since 2021, currently 73.6 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.

Fun facts about SIGA TECHNOLOGIES INC

Quirks, history, and lore behind SIGA — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in New York City.
  • 2
    The Numbers
    Annual revenue in the range of tens of millions of dollars, almost entirely dependent on a single product and government procurement contracts.
  • 3
    The History
    Founded in the late 1990s, the company spent years in development before landing a drug approval tied to one of the most feared bioterrorism threats on the planet.
  • 4
    The Secret
    Its primary customer isn't a hospital chain or pharmacy — it's the U.S. federal government, which stockpiles its drug in the Strategic National Stockpile.
  • 5
    The Lore
    When monkeypox outbreaks spike anywhere in the world, this company's stock price tends to spike right along with them — investors treat it as a biodefense barometer.
  • 6
    The Giveaway
    Its flagship drug TPOXX (tecovirimat) is the only FDA-approved oral treatment for smallpox — a disease officially eradicated, yet still worth defending against.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$6.2M

Net Income

Q1 2026

$-3.5M

Free Cash Flow

Q1 2026

$-8.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-0.9% YoY
$138.7MFY 2024
FY21 $133.7MFY22 $110.8MFY23 $139.9MFY24 $138.7M

Net Income

-13.0% YoY
$59.2MFY 2024
FY21 $69.5MFY22 $33.9MFY23 $68.1MFY24 $59.2M

Operating Income

-16.3% YoY
$70.0MFY 2024
FY21 $89.1MFY22 $42.7MFY23 $83.6MFY24 $70.0M

EPS (Diluted)

-13.7% YoY
$0.82FY 2024
FY21 $0.91FY22 $0.46FY23 $0.95FY24 $0.82

Total Assets

-3.9% YoY
$244.3MFY 2024
FY21 $214.7MFY22 $195.0MFY23 $254.4MFY24 $244.3M

Total Debt

FY 2024
FY21 FY22 FY23 FY24

Op. Cash Flow

-48.6% YoY
$48.8MFY 2024
FY21 $11.5MFY22 $41.6MFY23 $94.8MFY24 $48.8M

Get alerted when SIGA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SIGA TECHNOLOGIES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put SIGA on your watchlist

Track score changes the day SIGA TECHNOLOGIES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is SIGA a good stock to buy?

13F Pro's AI-powered analysis of SIGA TECHNOLOGIES INC (SIGA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SIGA are available on the SIGA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SIGA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SIGA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SIGA TECHNOLOGIES INC's investment landscape.